Oruka Therapeutics Aktie 137943588 / US6876041087
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
12.01.2026 13:58:00
|
Oruka Therapeutics Reports Positive Phase 1 Data For ORKA-002
(RTTNews) - Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.
The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.
Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.
Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.
On Friday, Oruka shares closed at $27.86, up 5.53%.
Analysen zu Oruka Therapeutics Inc Registered Shs
https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Oruka Therapeutics Inc Registered Shs | 27.40 | -1.44% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI schwächer -- DAX stabil -- Asiens Börsen schliessen in RotDer heimische Aktienmarkt gibt am Freitag nach, während der deutsche Leitindex seitwärts tendiert. An den Börsen in Fernost ging es am Freitag abwärts.